ArticleTherapeutics and clinical risk management2026
Efficacy and Safety of Anthracyclines Combined with Temozolomide Regimens for the Treatment of Advanced Leiomyosarcoma: A Retrospective Study.
Article in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiological Response to Capecitabine and Temozolomide in an Elderly Patient with Metastatic Leiomyosarcoma: A Case Report.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma with high rates of hematogenous metastasis and recurrent relapse, with a 5-year survival rate of 17.0%. This study evaluated the clinical efficacy of an anthracycline plus temozolomide (ATEM) regimen in advanced LMS and explored the feasibility of dynamic circulating tumor DNA (ctDNA) monitoring for early detection of disease progression. Methods: This retrospective study included patients with advanced LMS who received ATEM between September 2018 and December 2024. The efficacy, including complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), objective response rate (ORR), and disease control rate (DCR), as well as safety, were assessed. The median progression-free survival (mPFS) and median overall survival (mOS) were calculated using Kaplan-Meier survival curves. A subset of patients treated with TEM-containing regimens between December 2023 and December 2024 underwent longitudinal ctDNA monitoring. Results: Forty-seven patients were included, with a median follow-up of 39.5 months. The mPFS was 12.0 months and mOS was 37.5 months. One patient achieved clinical CR, 9 achieved PR, 33 had SD and 4 experienced PD. The ORR was 21.3% (10/47), and DCR was 91.5% (43/47). The most common adverse events were leukopenia (42.6%), neutropenia (32.0%), and thrombocytopenia (14.9%). Grade 4 neutropenia occurred in three patients, including one case complicated by febrile neutropenia. All cases were managed successfully with supportive treatment. No treatment-related deaths were observed. In this pilot investigation of 7 patients, ctDNA levels consistently reflected clinical disease status and treatment response. Conclusion: ATEM regimen demonstrated promising efficacy in advanced LMS, with survival outcomes comparable to or better than in prior first-line treatments. ctDNA monitoring showed promise as a non-invasive biomarker for disease monitoring and treatment guidance. Prospective, multi-center studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.